ProCE Banner Activity

Lessons From France on Implementing HCV Treatment as Prevention: Whom Should We Treat and How?

Clinical Thought
Now that clinicians outside of hospital settings can assess and treat HCV in France, which high-risk groups should we target for HCV “microelimination” and how? Here’s my take.

Released: April 23, 2019

Expiration: April 21, 2020

No longer available for credit.

Share

Faculty

Karine Lacombe

Karine Lacombe, MD, PhD

Professor of Medicine
Infectious Diseases Department
Sorbonne Uiversité
Inserm Pierre Louis School of Public Health
Paris, France

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by an educational grant from

Gilead

Partners

INHSU

ProCE Banner

Faculty Disclosure

Primary Author

Karine Lacombe, MD, PhD

Professor of Medicine
Infectious Diseases Department
Sorbonne Uiversité
Inserm Pierre Louis School of Public Health
Paris, France

Karine Lacombe, MD, PhD, has disclosed that she has received consulting fees from AbbVie, Gilead Sciences, and Janssen.